LMNGF News and Press, BioVaxys Technology From 11/17/21

BioVaxys Co-Founder and Chief Medical Officer David Berd, MD, to Present at World Vaccine & Immunotherapy Congress West Coast 2021 BioVaxys Co-Founder and Chief Medical Officer David Berd, MD, to Present at World Vaccine & Immunotherapy Congress West Coast 2021 Canad...

BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH Canada NewsWire VANCOUVER, BC , Nov. 9, 2021 /CNW/ --&#...

BioVaxys Further Expands Intellectual Property Portfolio in Global Markets Canada NewsWire - Files Applications for International Patent and Trademark Protection of CoviDTH VANCOUVER, BC , Oct. 28, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: B...

BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine Canada NewsWire VANCOUVER, BC , Oct. 20, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has filed with the United S...

BioVaxys Announces BVX-0320 Poster Presentation at ISIRV-WHO Virtual Conference PR Newswire SARS-Cov-2 spike protein vaccine induced strong antibody and T cell responses in murine model VANCOUVER, BC , Oct. 8, 2021 /PRNewswire/ -- BioVaxys Technology Corp...

BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission Canada NewsWire VANCOUVER, BC , Sept. 28, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ( "BioVaxys" or "Company"), announced today that it has started its planned ...

BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins Canada NewsWire - Potential for superior tolerability to mRNA and Adenovirus Vector vaccines - Production Agreement signed w...

BioVaxys Engages Life Sciences Public Relations and Market Communications Firm 6 Degrees PR Newswire VANCOUVER, British Columbia , Sept. 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ( "BioVaxys") announced today tha...

BioVaxys ENGAGES life sciENCES Public relations and market communications firm 6 degrees PR Newswire VANCOUVER, British Columbia , Sept. 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ( "BioVaxys") announced today tha...

BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone Canada NewsWire VANCOUVER, British Columbia , Sept. 17, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ( "BioVaxys"), announced today that ...